Andrew P. Garner

Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients

Andrew P. Garner, Joseph M. Gozgit, Rana Anjum et al. · Clinical Cancer Research · 2014 · 160 citations

Medicine, Oncology, Pharmacology +15

Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer

Meredith S. Eno, Jason D. Brubaker, John E. Campbell et al. · Journal of Medicinal Chemistry · 2022 · 160 citations · Full text

Medicine, Oncology, Pharmacology +14

An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin

Andrew P. Garner, Carl Uli Bialucha, Elizabeth R. Sprague et al. · Cancer Research · 2013 · 124 citations · Full text

Medicine, Oncology, Pharmacology +12

Nitric oxide synthases catalyze the activation of redox cycling and bioreductive anticancer agents.

Andrew P. Garner, Mark J. I. Paine, Ignacio Rodríguez‐Crespo et al. · PubMed · 1999 · 109 citations

Life Sciences, Biochemistry, Pharmacology +17

Effects of antiinflammatory agents and prostaglandins on acid and bicarbonate secretions in the amphibian-isolated gastric mucosa

Andrew P. Garner, Gunnar Flemström, Jon R. Heylings · Gastroenterology · 1979 · 107 citations

Life Sciences, Animal Sciences, Physiology +13